PPEPGAINS
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
PEPGAINS/LIBRARY/METABOLIC/SURVODUTIDE
WEIGHT LOSSPHASE 3 TRIALS

Survodutide.

The Dual Agonist for Weight & Liver Health
AKA · BI 456906 · Dual GLP-1/Glucagon
WEIGHT LOSSSUBCUTANEOUS

Dual GLP-1/glucagon receptor agonist showing impressive results for both weight loss and liver fat reduction. A promising alternative to tirzepatide with a different dual mechanism.

Jump to dosing ↓Read researchWhere to buy
~5-6 days (estimated)
Half-life
2
Citations
1
Routes
1
Categories
Research
Storage
60
Popularity

AT A GLANCE.

§ 01 · TL;DR

THE QUICK READ.

Dual GLP-1/glucagon receptor agonist showing impressive results for both weight loss and liver fat reduction. A promising alternative to tirzepatide with a different dual mechanism.

Activates both GLP-1 and glucagon receptors - GLP-1 for appetite suppression and glucagon for increased fat burning and liver fat reduction.

Currently in clinical trials - dosing protocols being optimized

WHAT IT MIGHT HELP WITH.

1
Up to 18.7% body weight loss in Phase 2
2
Significant liver fat reduction
3
Potential NASH/MASH treatment
4
Improved metabolic parameters
5
Weekly injection convenience

HOW IT WORKS.

§ 02 · MECHANISM

Activates both GLP-1 and glucagon receptors - GLP-1 for appetite suppression and glucagon for increased fat burning and liver fat reduction.

Dual agonist targeting GLP-1R for appetite/satiety regulation and GCGR for enhanced hepatic lipid oxidation, thermogenesis, and metabolic rate. The glucagon component provides additional energy expenditure benefits and potent effects on liver fat.

WHO IT'S FOR
  • ✓Those interested in cutting-edge weight loss options
  • ✓Patients with fatty liver disease/NASH
  • ✓Those who may benefit from glucagon-mediated fat burning
  • ✓Research compound enthusiasts
WHO SHOULD AVOID
  • ✕Those needing FDA-approved treatments now
  • ✕Medullary thyroid carcinoma history
  • ✕Severe GI conditions
  • ✕Pregnant/planning pregnancy

THE RESEARCH.

§ 03 · 2 STUDIES
2024 · FINDING
CITED

Phase 2 Obesity Trial

Up to 18.7% body weight loss at 46 weeks with dose-dependent efficacy

Source ↗
2024 · FINDING
CITED

MASH/NASH Study

Significant liver fibrosis improvement and potential for MASH resolution without worsening fibrosis

Source ↗

DOSING PROTOCOL.

§ 04 · DOSING
TYPICAL RANGE
Currently in clinical trials - dosing protocols being optimized
Titrated up to 4.8mg weekly (Phase 3 doses under investigation)
FREQUENCY
Most-cited schedule
Once weekly
ROUTES
Delivery methods
SUBCUTANEOUS
HALF-LIFE
Steady state drives frequency
~5-6 days (estimated)
STORAGE
Protect from light, refrigerate
Research protocols specify
⚠ NOTE

These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using Survodutide should work with a qualified physician and source from a supplier providing third-party COAs.

FORMS AVAILABLE
  • · Subcutaneous injection
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
Open dosing calculator →

SIDE EFFECTS & RISKS.

§ 06 · SAFETY
·
Nausea
Common (30-40%) · mild

Improves with titration

·
Vomiting
Common (15-20%) · mild
·
Diarrhea
Common (15%) · mild
·
Decreased appetite
Common · mild

WHERE TO SOURCE

§ 07 · SUPPLIER
PEAK LAB
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED

Survodutide is not currently stocked by our vetted supplier. If you're researching it, verify any source with a third-party COA — our full sourcing guide covers what to look for.

Sourcing guide →

COMMON QUESTIONS.

§ 08 · FAQ
How does survodutide differ from tirzepatide?
Tirzepatide targets GLP-1 and GIP receptors, while survodutide targets GLP-1 and glucagon receptors. The glucagon component may provide stronger effects on liver fat and energy expenditure.
When might survodutide be available?
Phase 3 trials are ongoing. If successful, FDA approval could come in 2025-2026, though regulatory timelines vary.
Is survodutide better for fatty liver?
The glucagon receptor activation specifically targets liver fat metabolism, which may make it particularly effective for NASH/MASH. Phase 2 showed impressive liver fat reduction.
Can I get survodutide outside clinical trials?
Survodutide is not approved for human use outside of clinical trials. Using unapproved compounds carries significant safety and quality risks.
◆ THE PEPGAINS DISPATCH

GET THE NEXT UPDATE FIRST.

New research on Survodutide + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.